Aw. Gomoll et al., EFFECT OF TIMING OF TREATMENT OF THE GLYBURIDE-REVERSIBLE CARDIOPROTECTIVE ACTIVITY OF BMS-180448, The Journal of pharmacology and experimental therapeutics, 281(1), 1997, pp. 24-33
The effect of the timing of treatment with the ATP-regulated potassium
channel agonist BMS-180448 was evaluated in isolated rat heart and fe
rret models of ischemia and reperfusion. In rat hearts, 10 mu M BMS-18
0448, given before and after global ischemia as well as only during re
flow, improved reperfusion contractile function and attenuated lactic
dehydrogenase release, although reperfusion-only treatment was less ef
fective. Cromakalim (10 mu M) and bimakalim (10 mu M) treatment before
and after global ischemia afforded a degree of protection similar to
that of BMS-180448, although they were not cardioprotective when given
only during reperfusion. Pre- and posttreatment cardioprotection were
abolished by glyburide. Ischemia/reperfusion significantly increased
cytosolic calcium concentration ([Ca++](i)) and BMS-180448 given only
during reperfusion attenuated this change. In anesthetized ferrets, BM
S-180448 (2 mg/kg) or vehicle was infused i.v. during a 40-min interva
l beginning 1) 10 min before coronary occlusion, 2) at the 45th min of
ischemia or 3) at the 5th min of reperfusion. Preocclusion administra
tion of BMS-180448 was associated with a 35% reduction in infarct dama
ge from that recorded in vehicle-treated control ferrets. Drug adminis
tered at the midpoint of ischemia reduced infarct size similar to 44%,
whereas delaying BMS-180448 infusion until the 5th min of reperfusion
reduced, but still provided a significant (17%) level of salvage. The
favorable effects of BMS-180448 in the ferret were not associated wit
h changes in either collateral blood flow or peripheral hemodynamics.
Thus BMS-180448 shows some protective effects when given only during r
eperfusion. Cromakalim and bimakalim did not exert similar actions and
the difference may be secondary to the faster penetration of BMS-1804
48.